Christopher Sweeney, MBBS, on Adding Enzalutamide to the Treatment Landscape for Metastatic Hormone-Sensitive Prostate Cancer

Posted: Sunday, June 2, 2019

Christopher Sweeney, MBBS, of Dana-Farber Cancer Institute, discusses how he sees enzalutamide fitting into the treatment landscape for testosterone suppression in metastatic hormone-sensitive prostate cancer.